You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab

Article metrics

Article menu
Immunotherapy biomarkers
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab

 

Online download statistics by month:

Online download statistics by month: March 2023 to February 2026

AbstractFullPdf
Mar 2023575590209
Apr 202332532570
May 202322322457
Jun 202316816837
Jul 202312012243
Aug 202314114228
Sep 2023939321
Oct 2023969723
Nov 2023888818
Dec 2023787937
Jan 2024808248
Feb 2024505017
Mar 20249710192
Apr 2024848430
May 2024858731
Jun 2024787729
Jul 2024616331
Aug 2024515023
Sep 2024626431
Oct 2024727235
Nov 2024575927
Dec 2024777830
Jan 2025757539
Feb 202517517526
Mar 2025555536
Apr 202511011034
May 2025606238
Jun 2025272711
Jul 2025110
Feb 2026200
Total326633001151